Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome—a case report - Summary - MDSpire

Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome—a case report

  • By

  • Yuxi Bai

  • Lidan Geng

  • Xiyue Yang

  • Qiuling Shi

  • Jie Li

  • Gang Feng

  • May 22, 2026

  • 0 min

Share

Objective:

To present a case of metachronous esophageal squamous cell carcinoma (SCC) developing after treatment for esophageal adenoid cystic carcinoma (ACC).

Key Findings:
  • The patient developed metachronous SCC outside the radiation field after treatment for ACC.
  • Histopathological examination confirmed the SCC with distinct immunohistochemical characteristics.
  • Complete remission was achieved following definitive chemoradiotherapy.
Interpretation:

The case illustrates the occurrence of second primary malignancies post-ACC treatment.

Limitations:
  • The rarity of esophageal ACC limits generalizability.
  • Long-term outcomes and potential late effects of treatment are not fully established.
Conclusion:

Comprehensive endoscopic surveillance is important for early detection of secondary primaries in patients treated for esophageal ACC.

Original Source(s)

Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome—a case report

  • by Yuxi Bai, Lidan Geng, Xiyue Yang, Qiuling Shi, Jie Li, Gang Feng

  • May 22, 2026

Related Content

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation